Article
Relapse risk and survival in patients with FLT3 mutated acute myeloid leukemia undergoing stem cell transplantation.
American journal of hematology - 1 Apr 2017
Gaballa Sameh, Saliba Rima, Oran Betul, Brammer Jonathan E, Chen Julianne, Rondon Gabriela, Alousi Amin M, Kebriaei Partow, Marin David, Popat Uday R, Andersson Borje S, Shpall Elizabeth J, Jabbour Elias, Daver Naval, Andreeff Michael, Ravandi Farhad, Cortes Jorge, Patel Keyur, Champlin Richard E, Ciurea Stefan O
Abstract excerpt
In patients with AML with FMS-like tyrosine kinase 3 (FLT3) mutations, the significance of minimal residual disease (MRD) detected by PCR before allogeneic stem cell transplantation (SCT) on outcomes after transplant remains unclear. We identified 200 patients with FLT3-AML who underwent SCT at our institution. Disease status at transplant was: first or second complete remission (CR1/CR2, n = 119), high-risk CR...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.